Utilisation and outcomes of allogeneic hematopoietic cell transplantation in Ontario, Canada, and New York State, USA: a population-based retrospective cohort study

Samantha Aliza Hershenfeld,1 John Matelski,2 Vicki Ling,3 Michael Paterson,3 Matthew Cheung,1,4 Peter Cram1,2

ABSTRACT

Objective Allogeneic haematopoietic cell transplantation (HCT) is a potentially curative treatment for haematologic and oncologic diseases. There is a perception that the United States of America (USA) offers greater access to expensive therapies such as HCT. Alternatively, Canada is thought to suffer from protracted wait times, but lower spending. Our objective was to compare HCT utilisation and short-term outcomes in Ontario (ON), Canada, and New York State (NY), USA.

Design, setting and participants We conducted a population-based cohort study using administrative health data to identify all residents of ON and NY who underwent allogeneic HCT between 2012 and 2015.

Primary and secondary outcome measures The primary outcome measures were age and sex standardised HCT utilisation rates, in-hospital mortality, hospital length of stay (LOS) and readmission rates in ON and NY. Secondary outcomes included comparing ON and NY HCT recipients with respect to demographic characteristics and patient wealth (using neighbourhood income quintile).

Results We identified 547 HCT procedures in ON and 1361 HCT procedures performed in NY. HCT recipients in ON were younger than NY (mean age 49.0 vs 51.6 years; p<0.001) and a lower percentage of ON recipients resided in affluent neighbourhoods compared with NY (47.2% vs 52.6%; p=0.026). Utilisation of HCT was 14.4 per 1 million population per year in ON and 26.7 per 1 million per year in NY (p<0.001). The magnitude of the ON–NY difference in utilisation was larger for older patients. In-hospital mortality, LOS and readmission rates were lower in ON than NY in both unadjusted and adjusted analyses.

Conclusions We found significantly lower utilisation of HCT in ON compared with NY, particularly among older patients. Higher in-hospital mortality in NY relative to ON requires further study. These differences are thought provoking for patients, healthcare providers and policymakers in both jurisdictions.

INTRODUCTION

Allogeneic haematopoietic cell transplantation (HCT) is a potentially curative treatment for multiple haematological and oncologic diseases including acute leukaemias, lymphomas, myelodysplastic syndromes (MDS) and other less common conditions.1–3 Clinical practice guidelines for HCT in Canada and the USA are quite similar and there is no obvious biological reason to suspect markedly different underlying differences in rates of haematologic conditions necessitating HCT.

Investigators in both countries commonly participate in large clinical trials and regularly update guidelines to reflect new evidence.1–3 The number of HCTs being performed globally has been increasing for the past decade as a consequence of a growing and ageing population, expansion of HCT to include older patients and new indications for HCT to include certain non-malignant conditions such as haemoglobinopathies.1–6–9 Increasing demand for HCT is challenging for payers because of the estimated costs of US$80 000–US$200 000 for the initial transplant and short-term (90 days) follow-up.10–12
Despite general agreement on the indications for HCT and relatively similar cancer incidence rates across countries,13–15 there are very few empirical studies comparing utilisation of HCT in different countries.16–18 Many of these studies are older and few include data from either Canada or the USA.

We sought to compare utilisation and short-term outcomes for HCT in Ontario (ON), Canada, and New York State (NY), USA. We were motivated by several factors, including widespread public concerns that erupted in ON in 2015 that HCT capacity was insufficient and that patients were suffering harm,19 20 but limited data characterising a shortfall in capacity.19 21 22 Moreover, Canada–USA comparison not only affords the opportunity to compare HCT in two countries with many similarities (a common border, close geopolitical relationships, racially diverse populations), but also striking differences in terms of culture, financing and delivery of healthcare services.23

Our a priori hypothesis was that ON would have lower per capita utilisation of HCT than NY and that HCT utilisation would be higher in both jurisdictions among residents from wealthier neighbourhoods. As prior Canada–USA comparison studies have demonstrated longer hospital length of stay (LOS) but lower readmission rates in Canada as compared with the USA,24 25 we also hypothesised in the present study that patients receiving HCT in ON would have a longer LOS, but lower readmission rates and similar short-term mortality.

**METHODS**

**Data**

We used population level administrative health data from ON and NY to identify all adults (age ≥18 years) who underwent inpatient allogeneic HCT between 2012 and 2015. Our primary data source for ON was the 2012–2015 Canadian Institute for Health Information Discharge Abstract Database (DAD), which has been extensively used for similar research studies. These administrative records provide information on all hospitalisations paid for by the Ontario Health Insurance Plan (OHIP); OHIP provides health insurance to all legal residents of ON (~99% of the population), which covers virtually 100% of inpatient hospitalisations.26 27 Though there have been some limited case series reporting outpatient HCT, these have generally described single-centre experiences, and the vast majority of HCT in both countries are performed in the inpatient setting.28–30 ON’s DAD provides information regarding patient demographics (age, sex), primary and secondary diagnoses coded using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM codes), discharge disposition, patient identifier and hospital identifier. Comorbid conditions present at the time of the index hospital stay were captured using algorithms developed by Elixhauser et al34 which has been used extensively in prior research studies.35

Estimates of the NY population were obtained from the US Census Data; estimates of the ON population were obtained from the analogous Canadian Census Data. We linked the NY data to the American Hospital Association annual survey to ascertain information regarding hospital teaching status and bed size. We linked the ON DAD to the OHIP Registered Persons Database for mortality information, and to information from the Ontario Ministry of Health and Long-Term Care for hospital characteristics. Multiple ON datasets were linked using unique encoded identifiers and analysed at ICES.

**Cohort generation**

We identified adults aged ≥18 years who underwent allogeneic HCT between 1 January 2012 and 30 September 2015 using CCI codes in ON and ICD-9-CM codes for NY that have been used in prior HCT research (online supplemental table 1).36–38 We excluded patients with missing age or sex, age ≥105 years at the time of their HCT, patients who underwent their HCT in 2011 but were subsequently discharged in 2012 and patients whose index hospital stay was implausibly short (≤1 day) because this would be incompatible with receiving an HCT. We excluded patients who died on the day of index procedure or prior to the index procedure. We excluded patients who had received HCT in the 2 years prior to study initiation (1 January 2010 to 31 December 2011) because the index procedure in such patients could represent a complication of an earlier HCT. We also limited our cohort to patients for whom HCT was listed in the primary procedure field in NY (or first procedure field in ON) to avoid counting readmissions or patients with a prior HCT as de novo procedures. We excluded patients who underwent a second hospitalisation for HCT within <180 days of the first HCT, as the second hospitalisation could represent a complication of the earlier procedure.

**Statistical analyses**

First, we compared demographics, comorbidities and the percentage of patients who resided in higher and lower
income neighbourhoods among patients in ON and NY using simple bivariate measures. In each jurisdiction, we used each patient’s zip code or postal code of residence to link them to their corresponding neighbourhood-level census data. Patients were then stratified into income quintiles (quintile 1=lowest income, quintile 5=highest income) and subsequently grouped into low (quintiles 1–2), intermediate (quintile 3) and high (quintile 4–5) groups. We compared the percentage of HCT recipients residing in low, intermediate and high income neighbourhoods in ON and NY. We performed an exploratory analysis assessing for common HCT indications using ICD-10 and ICD-9 for ON and NY based on coding schemes used in prior studies. As each patient record contains fields for multiple diagnoses, we selected the first relevant indication code that appeared, allowing for only a single indication for each patient.

Second, we compared the percentage of all acute care hospitals in ON and NY that performed HCT and mean/median annual hospital HCT volumes. We also compared ON and NY hospitals with respect to bed size and teaching status (teaching vs not).

Third, we compared per capita utilisation of HCT (procedures per 1 000 000 population per year) for adults in ON and NY. The numerator for these calculations was the total number of allo-HCTs performed in each jurisdiction while the denominator was the number of adults age ≥18 years in each jurisdiction derived from census data. We calculated age and sex standardised utilisation rates using a direct standardisation approach.

Fourth, we compared unadjusted outcomes in ON and NY including hospital LOS, in-hospital mortality and hospital readmission within 30 and 180 days of discharge among those who survived to discharge. We conducted stratified analyses comparing demographics and in-hospital mortality among HCT recipients in ON and NY who were older and younger than 60 years of age. Finally, we used generalised estimating equations to compare risk-standardised outcomes in ON and NY using two sequential models: Model 1 adjusted for only patient age and sex; Model 2 for Model 1 factors plus hospital HCT volume and LOS.

Our study protocol and analyses were prespecified (online supplemental appendix 1) and registered with Open Science prior to the initiation of any statistical analysis. All analyses were performed using either SAS (Version 9.4, Cary, North Carolina) or R statistical software packages.

**Patient and public involvement**

It was not appropriate or possible to involve patients or the public in the design, or conduct, or reporting, or dissemination plans of our research. However, our study was motivated by both public and government concerns about whether ON was providing adequate numbers of HCT. Our results will be disseminated to the ON government and the public in accordance with the ICES policies.

**RESULTS**

Our cohort consisted of 547 HCT procedures in ON performed on 545 individual patients and 1361 procedures performed on 1333 individual patients in NY between 2012 and 2015 (online supplemental figure 1A,B). The mean age of patients who received HCT in ON was significantly younger than NY (49.0 vs 51.6; p<0.001) while the percentage of HCT recipients who were women was similar between jurisdictions (table 1). There were significant differences between jurisdictions in the indication for HCT (table 1). For example, acute myeloid leukaemia (AML) was listed as the primary diagnosis in ON and NY for 41.8% and 22.2% of HCTs, respectively, (p<0.001), while MDS was the primary diagnosis for 9.9% in ON and 11.8% in NY (p=0.28) (table 1). A higher percentage of HCT recipients in NY resided in affluent neighbourhoods (quintiles 4 or 5) compared with ON (52.6% in NY vs 47.2% in ON; p=0.04) (table 1). A smaller percentage of ON patients underwent 2 or more HCTs relative to NY (p=0.02).

In ON, 2.4% of acute hospitals performed HCT as compared with 5.4% in NY (p=0.16), which represents 3.7 and 7.8 hospitals performing HCT per 10 million population, respectively. Mean annual hospital HCT volumes were similar in ON and NY (38.8 vs 32.4; p=0.10) (table 2).

The overall utilisation of HCT was significantly lower in ON than NY (14.4 vs 26.7 HCTs per million adult population per year [p<0.001]) (table 3). The ON–NY difference in utilisation was relatively small among younger adults (eg, 4.9 fewer HCTs per million in ON as compared with NY among adults age <50 years), but increased progressively with increasing age (figure 1 and table 3).

Unadjusted LOS was shorter in ON than NY (33.6 vs 36.3 days; p=0.01) and in-hospital mortality was lower in ON compared with NY (3.7% vs 6.4%; p=0.02) (table 4). When stratified by age, younger HCT recipients (age <60) had similar in-hospital mortality in ON and NY (4.6% vs 6.7%; p=0.17), whereas older recipients (age ≥60) had lower in-hospital mortality in ON compared with NY (1.3% vs 5.9%; p=0.02). The significantly lower in-hospital mortality in ON compared with NY persisted in analyses adjusting for age, sex, LOS and hospital volume (online supplemental table 2).

Unadjusted rates of hospital readmission within 30 and 180 days of hospital discharge were both significantly lower in ON compared with NY (table 4). In adjusted analyses, compared with patients in NY, patients in ON had significantly lower LOS and lower 30-day readmission rates (online supplemental table 2).

A secondary analysis compared demographics between HCT recipients stratified by age (<60 compared with ≥60 years) (online supplemental table 3). The differences in comorbidities between ON and NY were similar to the non-stratified analysis, with most comorbidities, such as,
Congestive heart failure and hypertension present less often in ON than in NY. Differences between indications were also similar, with AML being a more common indication in ON compared with NY, and unspecified indication more common in NY in both age groups. A higher percentage of the age ≥60 years HCT recipients in NY resided in the highest income quintiles compared with ON, whereas there was no significant differences between ON and NY with respect to HCT recipient income quintile in the age <60 years group.

**DISCUSSION**

In an analysis of administrative data from ON, Canada, and NY, USA, we found significant differences in utilisation and outcomes of HCT. While overall per capita utilisation of HCT was approximately 60% higher in NY than in ON, utilisation was 200% higher in NY among adults age ≥60 years of age. Unexpectedly, we observed significantly lower in-hospital mortality in ON that persisted even after adjustment for differences in age. In aggregate, our study provides compelling evidence of the importance of cross-border comparative studies and provides important lessons for healthcare providers and policymakers in both jurisdictions.

Several of our findings warrant elaboration. First, our finding of significantly lower utilisation of HCT in ON compared with NY adds important data to the contentious debate over access to HCT in ON. In 2015, there was widespread media coverage in ON suggesting that HCT capacity was insufficient after several tragic deaths of Canadian patients with haematologic conditions. In response, the ON government made substantial investment to expand capacity, including funding a new HCT centre. We found virtually no existing empirical data describing HCT utilisation in ON or how utilisation rates in ON compare with other countries. Without such information, policymakers in ON (or any other jurisdiction) lack empirical data to guide crucial decisions about whether access to HCT is adequate.

In understanding our study, it is important to review the existing research on HCT utilisation. Gratwohl et al used 2006 data from centres participating in the Worldwide Network for Bone Marrow Transplant to study utilisation of both autologous and allogeneic HCT across 71 countries. They found a lower utilisation rate in Canada (reported as between 5 and 30 HCTs per million population per year) compared with the USA (>30 per million per year) but their study lacked the granularity of our analysis, and included both autologous and allogeneic HCT. Our study adds significantly to the existing literature on HCT utilisation differences by capturing all allogeneic HCTs performed on adult residents of each jurisdiction over our study period, thus providing accurate measures of the true number of HCTs.

---

**Table 1** Characteristics of patients who underwent allogeneic haematopoietic cell transplantation in Ontario and New York in 2012–2015

| Characteristic                        | Ontario (N=545) | New York (N=1333) | P value |
|--------------------------------------|----------------|------------------|---------|
| Age, mean(SD)                        | 49.0 (13.7)    | 51.6 (14.1)      | <0.001  |
| Age, <50, number (%)                 | 241 (44.2)     | 489 (36.7)       | 0.002   |
| Age, 50–59, number (%)               | 159 (29.2)     | 376 (28.2)       | 0.67    |
| Age, 60–69, number (%)               | 136 (25.0)     | 400 (30.0)       | 0.03    |
| Age, ≥70, number (%)                 | 9 (1.7)        | 68 (5.1)         | 0.001   |
| Female, N (%)                        | 239 (43.9)     | 581 (43.6)       | 0.92    |

**Comorbid conditions**

- Congestive heart failure: 11 (2.0) ON vs 91 (6.8) NY, <0.001
- Depression: 33 (6.1) ON vs 185 (13.9) NY, <0.001
  - Hypertension with complications: 0 (0.0) ON vs 445 (33.4) NY, <0.001
- Diabetes without complications: 56 (10.3) ON vs 110 (8.3) NY, 0.16
- Chronic obstructive pulmonary disease: 19 (3.5) ON vs 108 (8.1) NY, <0.001
- Renal failure: 11 (2.0) ON vs 47 (3.5) NY, 0.09

**Indications**

- AML: 228 (41.8) ON vs 296 (22.2) NY, <0.001
- MDS: 54 (9.9) ON vs 157 (11.8) NY, 0.28
- ALL: 59 (10.8) ON vs 113 (8.5) NY, 0.11
- CML: 29 (5.3) ON vs 51 (3.8) NY, 0.15
- CLL: 24 (4.4) ON vs 34 (2.6) NY, 0.04
- Non-Hodgkin’s lymphoma: 9 (1.7) ON vs 87 (6.5) NY, <0.001
- Multiple myeloma: 10 (1.8) ON vs 34 (2.6) NY, 0.35
- Unspecified/other: 132 (24.3) ON vs 718 (53.9) NY, <0.001

**Neighbourhood income**

- Income quintiles 1–2: 184 (33.8) ON vs 421 (31.7) NY, 0.36
- Income quintile 3: 104 (19.1) ON vs 209 (15.7) NY, 0.07
- Income quintile 4–5: 257 (47.2) ON vs 699 (52.6) NY, 0.04

*Quintile 1=lowest income neighborhood; Quintile 5=highest income neighborhood.

ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; MDS, myelodysplastic syndrome.

**Table 2** Characteristics of hospitals that performed HCT in Ontario and New York

| Characteristic                        | Ontario (N=165) | New York (N=224) | P value |
|--------------------------------------|----------------|-----------------|---------|
| Hospitals performing procedure, number (%) | 4 (2.4)       | 12 (5.4)        | 0.16    |
| Annual procedural volume, mean (SD)   | 38.8 (41.1)    | 32.4 (32.9)     | 0.10    |
| Annual procedural volume, median (IQR) | 27 (15–63)    | 22.9 (8.9–49.6) | N/A     |
| Bed number, mean (SD)                | 600 (240)      | 1244.8 (759.1)  | <0.001  |

Hershenfeld SA, et al. BMJ Open 2020;10:e039293. doi:10.1136/bmjopen-2020-039293
performed. Our study provides convincing evidence that HCT utilisation is lower in ON than in NY. While it might be tempting to jump to the conclusion that our study provides evidence that HCT utilisation is too high in NY or too low in ON, we would argue against hasty assumptions. In particular, we lack detailed clinical data that would allow us to ascertain the ‘appropriateness’ of HCT at the individual patient level.

Second, our study should be considered in the context of the economic implications of expanding HCT utilisation in ON or reducing utilisation in NY, recognising that we lack the nuanced data to determine precisely what the ideal utilisation rate might be. It should be noted that healthcare spending is far lower in Canada than in the USA (11.5% vs 17.6% of gross domestic product in 2015). The cost of HCT has been estimated at US$80 000–US$200 000 during the 90 days post transplant period. If ON were to increase HCT utilisation to the NY rate (eg, from 14 per million to 26 per million), this would translate into an additional 105 HCTs annually at a cost of approximately US$10 500 000. Alternatively, if NY were to reduce the yearly HCT rate by 25% from 26 per million to 20 per million per year, this would translate into 90 fewer HCTs per year in NY and a US$13 500 000 reduction in spending. Again, it is important to stress that we lack clear data on what the correct utilisation rate might be, but considering the cost implications is instructive.

Figure 1  Haematopoietic cell transplantation (HCT) utilisation in Ontario and New York. Utilisation rates in Ontario and New York reported as procedures per 1 000 000 adult population per year, stratified by HCT recipient age. Utilisation for New York directly standardised to match the age and sex of the Ontario population.
Our study has several limitations. Our analysis is limited to administrative data from one Canadian province and one US state, which may impact generalisability of our results to the national level. Second, we lacked detailed clinical data with respect to patient comorbidities and indications for HCT and were limited to the detail included in our administrative data. The prevalence of common comorbidities such as hypertension in ON appears to be quite low relative to NY, which is almost certainly an artefact of differences in coding practices rather than a true reflection of the burden of comorbidities in the population. This precludes us from comparing ON and NY HCT recipients with respect to comorbidities, which would be important in interpreting the differences in outcomes we observed. Indications for HCT were inferred based on ICD codes in administrative databases. However this analysis should be considered exploratory and interpreted with caution; 24.3% of ON patients and 53.9% of NY patients did not have any common indication coded for HCT, which makes it difficult to draw conclusions around whether differences in indications impact HCT practice in the two jurisdictions. Future studies comparing indications for HCT between the two regions are warranted. Third, though our study demonstrates a significant difference in HCT utilisation between ON and NY, we are unable to definitively comment on overuse and/or underuse in each jurisdiction. Fourth, while our study provides important data on utilisation in ON and NY both overall and stratified by age, we did not examine whether access to HCT is distributed equitably across other important variables such as socioeconomic status, race/ethnicity, or geography (rural/urban); it would be interesting to know whether Canada’s universal health insurance coverage might mitigate some of the socioeconomic differences recently reported by Paulson et al. Fourth, While HCT in both jurisdictions is virtually exclusively performed in the inpatient setting, it is possible that some components of the

Third, our finding that the higher HCT utilisation in NY relative to ON was relatively modest in younger adults (e.g., 20% higher at age <50), but increased progressively with advancing age (100% higher at age 50–59, 650% higher at age >70) is noteworthy. The American Society for Blood and Marrow Transplantation 2015 HCT guidelines specifically say that ‘age by itself should not be a contraindication to transplantation in patients who may benefit from this procedure’. Other agencies such as Cancer Care Ontario (CCO) and the European Society for Bone Marrow Transplantation are also non-specific, pointing out that global health and frailty are more important considerations than chronologic age. Our finding of significantly higher in-hospital mortality in NY compared with ON, largely driven by significantly higher mortality for patients of age ≥60 years in NY relative to ON warrants careful thought. The higher mortality observed in NY persisted in analyses that adjusted for age, sex and hospital volume adding robustness to our analyses. Given the implausibly large differences in comorbidity between our ON and NY HCT recipients and our lack of detailed clinical information required to calculate the Haematopoietic Cell Transplant-specific Comorbidity Index, we are unable to adjust for comorbid illness. Nevertheless, the higher short-term mortality we observed in NY clearly warrants further study and verification.

A number of other findings warrant brief mention. We observed differences in the primary indication identified for HCT with ON having a higher proportion of patients with AML, and NY a higher proportion of patients with unspecified indications. There are small but significant differences in HCT guidelines, with The American Society of Bone and Marrow Transplantation listing HCT as standard of care for haemoglobinopathies, myeloproliferative neoplasms, and immunodeficiency syndromes while CCO remarks that due to limited evidence, they are unable to provide guidance for these conditions. However, we would urge readers to interpret the incidence of indications for HCT in our study with caution, serving more as an exploratory analysis requiring further study. The administrative databases used lacked granular detail regarding indications for HCT; and furthermore, the reliability of ICD codes for some commonly transplanted conditions have not been thoroughly studied in the literature.

Our finding that a similar percentage of hospitals in ON and NY offered HCT with similar mean volumes was unexpected as we hypothesised a smaller percentage of ON hospitals would perform HCT but with higher volumes. However, the lower median volume in NY does suggest a larger proportion of low-volume HCT centres in NY. The number of HCTs we identified in ON correlate well with numbers reported by CCO, while the numbers from NY correlate reasonably well with numbers reported by the Center for International Blood and Marrow Transplant Research, adding rigour to our findings.

Our study has several limitations. Our analysis is limited to administrative data from one Canadian province and one US state, which may impact generalisability of our results to the national level. Second, we lacked detailed clinical data with respect to patient comorbidities and indications for HCT and were limited to the detail included in our administrative data. The prevalence of common comorbidities such as hypertension in ON appears to be quite low relative to NY, which is almost certainly an artefact of differences in coding practices rather than a true reflection of the burden of comorbidities in the population. This precludes us from comparing ON and NY HCT recipients with respect to comorbidities, which would be important in interpreting the differences in outcomes we observed. Indications for HCT were inferred based on ICD codes in administrative databases. However this analysis should be considered exploratory and interpreted with caution; 24.3% of ON patients and 53.9% of NY patients did not have any common indication coded for HCT, which makes it difficult to draw conclusions around whether differences in indications impact HCT practice in the two jurisdictions. Future studies comparing indications for HCT between the two regions are warranted. Third, though our study demonstrates a significant difference in HCT utilisation between ON and NY, we are unable to definitively comment on overuse and/or underuse in each jurisdiction. Fourth, while our study provides important data on utilisation in ON and NY both overall and stratified by age, we did not examine whether access to HCT is distributed equitably across other important variables such as socioeconomic status, race/ethnicity, or geography (rural/urban); it would be interesting to know whether Canada’s universal health insurance coverage might mitigate some of the socioeconomic differences recently reported by Paulson et al. Fourth, While HCT in both jurisdictions is virtually exclusively performed in the inpatient setting, it is possible that some components of the

### Table 4 Unadjusted outcomes for recipients of Haematopoietic cell transplantation in Ontario and New York

|                          | Ontario (N=547) | New York (N=1361) | P value |
|--------------------------|-----------------|-------------------|---------|
| **Length of stay, mean (SD)**<br>32.6 (17.9) | 36.3 (23.4) | <0.001 |
| **Discharge disposition**<br>Died in-hospital, number (%)<br>17 (3.1) | 87 (6.4) | 0.01 |
| **Home, number (%)**<br>486 (88.8) | 1231 (90.4) | 0.29 |
| **Transfer to another acute care hospital, number (%)**<br>33 (6.0) | 2 (0.1) | <0.001 |
| **Post acute care, (%)**<br>11 (2.0) | 40 (2.9) | 0.26 |
| **Readmission**<br>30-day hospital readmission, number (%)<br>140 (26.4) | 393 (30.8) | 0.06 |
| **180-day hospital readmission, number (%)**<br>303 (57.2) | 784 (61.5) | 0.08 |
| **Number of rehospitalisations per patient at 180 days, mean (SD)**<br>1.8 (1.2) | 1.4 (1.7) | <0.001 |

*1 patient in New York was discharged to ‘other’ location.
HCT could be performed in the outpatient setting. Our reliance on inpatient data prevents us from exploring this issue. Lastly, while the administrative databases used in this study, we are limited to in-hospital mortality as an outcome and are unable to comment on deaths that occurred after discharge or longer term outcomes. Similarly, we were unable to accurately assess cause of death using the data we had available. Further studies comparing longer-term survival post HCT and cause of death in ON and NY are needed.

In conclusion, we found that ON has significantly lower utilisation of HCT compared with NY, particularly at older age. We also observed significantly higher mortality in NY that did not appear to be explained by differences in age. Overall our results provide much needed information on HCT utilisation and outcomes that should be considered by healthcare providers and policy-makers in both jurisdictions.

REFERENCES

1. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant* 2015;21:1863–9.

2. Imrie K, Rumble RB, Crump M. The Advisory Panel on Bone Marrow and Stem Cell Transplantation: Hematology Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care. *Stem Cell Transplantation in Adults*. Toronto, ON: Cancer Care Ontario, Program in Evidence-based Care Recommendation Report, 2009.

3. Olszanski DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. *Biol Blood Marrow Transplant* 2009;15:137–72.

4. Olszanski DM, Appelbaum F, Cassileth PA, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. *Biol Blood Marrow Transplant* 2008;14:137–80.

5. Koreth J, Schlenck R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. *JAMA* 2009;301:2349–61.

6. Cancer Care Ontario. Complex malignant hematopoietic services in Ontario, 2017. Available: https://archive.cancercare.on.ca/common/pages/UserFile.aspx?fileld=381199 [Accessed 1 May 2019].

7. Center for International Blood and Marrow Transplant Research. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides, 2018. Available: https://www.cibmr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx [Accessed 1 May 2019].

8. Passweg JR, Baldomero H, Bader P, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for blood and marrow transplant activity survey report. *Bone Marrow Transplant* 2017;52:811–7.

9. Passweg JR, Baldomero H, Basak GW, et al. The EBMT activity survey report 2017: a focus on allo-HCT for nonmalignant indications and on the use of non-HCT cell therapies. *Bone Marrow Transplant* 2019;54:1575–85.

10. Majhail NS, Mau LW, Denzen EM, et al. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. *Bone Marrow Transplant* 2013;48:294–300.

11. Khera N, Zel lidat SB, Lee SJ. Economics of hematopoietic cell transplantation. *Blood* 2012;120:1545–51.

12. Preusssler JM, Denzen EM, Majhail NS. Costs and cost-effectiveness of hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 2012;18:1620–8.

13. Shysh AC, Nguyen LT, Guo M, et al. The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: a retrospective cohort study. *BMJ Public Health* 2017;18:94.

14. Cancer Statistics Center, American Cancer Society. Leukemia at a glance. Available: https://cancerstatisticscenter.cancer.org/?ga=2.135542264.871561029.1564442262-1315160246.1564442262#/cancer-site/Leukemia [Accessed 1 May 2019].

15. Canadian Cancer Study, Government of Canada. Canadian cancer statistics 2015: special topic: predictions of the future burden of cancer in Canada. Available: http://www.cancer.ca/~media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Cancer%20Statistics-2015-EN.pdf?la= en [Accessed 1 May 2019].

16. Gratwohl A, Passweg J, Baldomero H, et al. Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe. *Br J Haematol* 2002;117:451–68.

17. Gratwohl A, Hermans J, Goldman JM, et al. Bone marrow transplantation in Europe: major geographical differences. The European Group for Bone Marrow Transplantation [EBMT]. *J Intern Med* 1993;233:333–41.

18. Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. *JAMA* 2010;303:1617–24.

19. Canadian Broadcasting Corporation website. Her dying wish. Ontario parents want speedier stem cell transplants after daughter’s death. Available: https://www.cbc.ca/radio/asinthepicker/as-it-happens-thursday-episode-1.3568451/her-dying-wish-ontario-parents-want-speedier-stem-cell-transplants-after-daughter-s-death-1.3568464 [Accessed 20 Apr 2019].

20. The Star website. Ontario opens access to more stem-cell transplants. Available: https://www.thestar.com/news/canada/2016/05/01/ontario-opens-access-to-more-stem-cell-transplants.html [Accessed 20 Apr 2019].

21. Canadian Broadcasting Corporation website. Ontario spending millions sending cancer patients to U.S. for stem cell transplants,
Open access

auditor finds. Available: https://www.cbc.ca/news/canada/toronto/auditor-general-report-2017-healthcare-cancer-1.4435567 [Accessed 20 Apr 2019].

22 City News Toronto website. Leukemia patients wait up to three months for stem cell transplant. Available: https://toronto.citynews.ca/2015/06/22/leukemia-patients-wait-up-to-three-months-for-stem-cell-transplant/ [Accessed 20 Apr 2019].

23 Ridic G, Gleason S, Ridic O. Comparisons of health care systems in the United States, Germany and Canada. Mater Sociomed 2012;24:112–20.

24 Cram P, Landon BE, Matelski J, et al. Hip and knee arthroplasty utilization and outcomes in the United States and Canada: an analysis of new York and Ontario administrative data. Arthritis Rheumatol 2018;70:547–54.

25 Cram P, Landon BE, Matelski J, et al. Utilization and outcomes for spine surgery in the United States and Canada. Spine 2019;44:1371–80.

26 Ravi B, Jenkinson R, Austin PC, et al. Relation between surgeon volume and risk of complications after total hip arthroplasty: propensity score matched cohort study. BMJ 2014;348:g3284.

27 Stukel TA, Fisher ES, Alter DA, et al. Association of hospital spending intensity with mortality and readmission rates in Ontario hospitals. JAMA 2012;307:1037–45.

28 Granot N, Storer BE, Cooper JP, et al. Allogeneic hematopoietic cell transplantation in the outpatient setting. Biol Blood Marrow Transplant 2019;25:2152–6.

29 Guru Murthy GS, Hari PN, Szabo A, et al. Outcomes of reduced-intensity conditioning allogeneic hematopoietic cell transplantation performed in the inpatient versus outpatient setting. Biol Blood Marrow Transplant 2010;16:297–303.

30 McDermid S, Hutton B, Atkins H, et al. Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes. Bone Marrow Transplant 2010;45:1220–6.

31 Sanchez L, Sylvester M, Parondo R, et al. In-Hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a population-based study. Biol Blood Marrow Transplant 2017;23:1293–7.

32 White C. Cutting Medicare Hospital prices leads to a spillover reduction in hospital discharges for the nonelderly. Health Serv Res 2010;45:689–96.

33 Ko DT, Tu JV, Sandadavishvili Z, et al. Temporal trends in the use of percutaneous coronary intervention and coronary artery bypass surgery in New York state and Ontario. Circulation 2010;121:2635–44.

34 Kho DT, Tu JV, Sandadavishvili Z, et al. Temporal trends in the use of percutaneous coronary intervention and coronary artery bypass surgery in New York state and Ontario. Circulation 2010;121:2635–44.

35 Niederwieser D, Baldomero H, Szer J, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the worldwide network for blood and marrow transplantation group including the global board. Bone Marrow Transplant 2016;51:778–85.

36 Mohamed SYA, Fadhil I, Hamladji R-M, et al. Hematopoietic stem cell transplantation in the western Mediterranean region (EMR) 2008-2009: report on behalf of the eastern Mediterranean bone marrow transplantation (EMBMT) group. Hematol Oncol Stem Cell Ther 2011;4:81–93.

37 Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant 2016;51:786–92.

38 Centers for Medicare and Medicaid Services. National health expenditures by type of service and source of funds, cy 1960-2018, 2019. Available: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical [Accessed 25 Jul 2020].

39 Canadian Institute for Health Information. National health expenditure trends 1975–2019. Ottawa, 2019. https://www.cihi.ca/en/national-health-expenditures-trends-1975-to-2019

40 Canadian Institute for Health Information. International statistical classification of diseases and related health problems tenth revision, Canada. Available: https://www.cihi.ca/en/icd_volume_one_2015_en.pdf [Accessed 1 May 2019].

41 Baltiunas D, Patra J, Rehm J, et al. Smoking-attributable morbidity: acute care hospital diagnoses and days of treatment in Canada, 2002. BMC Public Health 2005;5:47.

42 Mahoney CA, Conklin EA. Factors affecting receipt of expensive cancer treatments and mortality: evidence from stem cell transplantation for leukemia and lymphoma. Health Serv Res 2015;50:197–216.

43 Sanchez L, Sylvester M, Parondo R, et al. In-Hospital mortality and post-transplantation complications in elderly multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a population-based study. Biol Blood Marrow Transplant 2017;23:1293–7.

44 Reich C, Ryan PB, Stang PE, et al. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform 2012;45:689–96.

45 Center for Medicare and Medicaid Services. National health expenditure trends 1975–2019. Ottawa, 2019. Available: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical [Accessed 25 Jul 2020].

46 Carreras E, Dufour C, Mohty M, et al. The EBMT Handbook. 2019 ed. Switzerland: Springer Open, 2019. https://www.ebmt.org/sites/default/files/2019-01/2019_Book_TheEBMTHandbook. pdf

47 Pervez ML. Comorbidities and hematopoietic cell transplantation outcomes. Hematol Am Soc Hematol Educ Program 2010;2010:237–47.

48 Health Resources & Services Administration. Transplant activity report covering 2013-2017. Available: https://bloodstecell.hrsa.gov/sites/default/files/bloodstecell/data/transplant-activity/transplants-year-cell-source-state-donor.pdf [Accessed 3 Mar 2020].

49 Paulson K, Brazauskas R, Khera N, et al. Inferior access to allogeneic transplant in disadvantaged populations: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant 2019;25:2086–90.